Sphera Funds Management LTD. trimmed its holdings in shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) by 4.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 321,430 shares of the company’s stock after selling 14,557 shares during the period. Sphera Funds Management LTD. owned 1.10% of Corvus Pharmaceuticals worth $2,758,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in CRVS. Cowen Inc. acquired a new stake in Corvus Pharmaceuticals during the 2nd quarter valued at $5,868,000. BlackRock Inc. increased its stake in shares of Corvus Pharmaceuticals by 51.9% in the 2nd quarter. BlackRock Inc. now owns 1,119,507 shares of the company’s stock valued at $12,290,000 after buying an additional 382,389 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Corvus Pharmaceuticals by 66.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 260,701 shares of the company’s stock valued at $2,237,000 after buying an additional 104,230 shares during the period. International Biotechnology Trust PLC acquired a new stake in shares of Corvus Pharmaceuticals in the 2nd quarter valued at $892,000. Finally, Renaissance Technologies LLC increased its stake in shares of Corvus Pharmaceuticals by 22.2% in the 3rd quarter. Renaissance Technologies LLC now owns 396,900 shares of the company’s stock valued at $3,405,000 after buying an additional 72,000 shares during the period. 87.42% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have recently commented on CRVS shares. Cowen reissued a “buy” rating on shares of Corvus Pharmaceuticals in a research note on Friday, November 2nd. Credit Suisse Group raised Corvus Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the company from $11.00 to $15.00 in a research note on Wednesday, August 15th. BidaskClub raised Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, September 1st. Finally, Zacks Investment Research cut Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 9th. One analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $13.58.
Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings results on Thursday, November 1st. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.12. On average, equities analysts predict that Corvus Pharmaceuticals Inc will post -1.77 EPS for the current year.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Recommended Story: What is the Consumer Price Index (CPI)?
Want to see what other hedge funds are holding CRVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corvus Pharmaceuticals Inc (NASDAQ:CRVS).
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.